Close
FINDING CURES TOGETHER<sup>SM</sup>

Translational Cancer Research for Basic Scientists Workshop

Program 


Sunday, Nov. 4 

Registration
2-7:30 p.m.


Welcome: A Conversation with the Course Directors
4-4:30 p.m.

George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Susan Band Horwitz, PhD, Albert Einstein College of Medicine, Bronx, New York
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts


Workshop Alumni Panel: From Bench to Bedside – How to Translate a Basic Science Study to the Clinic
4:30-6 p.m.


Opening Keynote Presentation
6-7 p.m.

Title to be announced
William G. Kaelin, Jr., Dana-Farber Cancer Institute, Boston, Massachusetts


Introductions: Workshop Participants
7-7:30 p.m.

George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Susan Band Horwitz, PhD, Albert Einstein College of Medicine, Bronx, New York
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts


Opening Reception and Dinner
7:30-9 p.m.


Top of page


Monday, Nov. 5 

Continental Breakfast
7-8 a.m.


Pre-Test (required)
8-8:30 a.m.


Introduction to Cancer Medicine and Diagnostics
8:30-9:45 a.m.

Overview
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts

Overview of pathology and molecular tools in diagnostics
Lynette M. Sholl, MD, Brigham and Women's Hospital, Boston, Massachusetts

Title to be announced


Break
9:45-10 a.m.


Introduction to Cancer Medicine and Diagnostics (continued)
10-11:30 a.m.

Cancer imaging: The role of imaging in oncology
Lawrence H. Schwartz, MD, Columbia University Medical Center, New York, New York

EGFR mutant lung cancer: From clinic to bench to back to clinic
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts

Panel Discussion and Questions: Personalized Cancer Medicine and What It Means in the Clinic


Buffet Lunch
11:30 a.m.-12:30 p.m.


Offsite Laboratory Visits
12:30-5 p.m.
Dana-Farber Cancer Institute
*Transportation will be provided
.

Surgical Pathology Laboratory tour and discussion
Diagnostic Radiology Laboratory tour and discussion
*Workshop attendees visit both laboratories during the time allotted.


Group Buffet Dinner
5-6 p.m.


Study Design Track: Project Meeting #1
Those who are in the Project Meeting will miss the One-on-One Meetings.
5:45-7:15 p.m.


One-on-One Meetings ("Office Hours")
6-7 p.m.


How Treatment Decisions Are Made
7:15-8:15 p.m.

George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Lynette M. Sholl, MD, Brigham and Women's Hospital, Boston, Massachusetts


Top of page


Tuesday, Nov. 6 

Continental Breakfast
7-8 a.m.


The Environment of Clinical Investigations
8-10:30 a.m.

Clinical research: An overview    
Peter C. Adamson, MD, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

Human subjects considerations in translational research
Mark E. Robson, MD, Memorial Sloan Kettering Cancer Center, New York, New York

Protection of human research participants
Alison Bateman-House, NYU School of Medicine, New York, New York

Why quantitative reasoning is important in translational cancer research
Mimi Kim, Albert Einstein College of Medicine, New York, New York

Panel Discussion


Break / Group Photo

10:30-11:30 a.m.


Offsite IRB Observational Visit
11:30 a.m.-2 p.m.    
Dana-Farber Cancer Institute
*Transportation will be provided.

Participants observe a live Institutional Review Board (IRB) session in order to gain insights into issues of protection of human subjects that are at the heart of translational research. One to two weeks beforehand, application titles will be shared with the attendees if possible.

Lunch / Overview of IRB
George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts

Observation of Live IRB Session

Panel Discussion and Questions on Live IRB Session


Orientation / Questions for Cancer Patient Clinic Visits
2-2:30 p.m.

George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts  
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts 


Free Time
2:30-4 p.m.


Study Design Track: Project Meeting #2
3-4:30 p.m.


One-on-One Meetings (”Office Hours”)
4-5:30 p.m.


Group Buffet Dinner
5:30-6:30 p.m.


Small Group Discussion Sessions with Clinician and Patient
6:30-8 p.m.

Each small group consists of a clinician, a patient, and approximately 10-15 workshop attendees. This provides a comfortable environment and encourages interaction. We ask doctors to share their perspectives as clinicians and researchers and patients to speak about whatever they feel most comfortable sharing regarding their experiences as patients/clinical trial participants.


Top of page


Wednesday, Nov. 7 

Continental Breakfast
7:45-8:45 a.m.


Offsite Patient Clinic Visits
8:45 a.m.-12 p.m.
Dana-Farber Cancer Institute
Massachusetts General Hospital
*Transportation will be provided.


Buffet Lunch
12-1 p.m.


The Research and Development Process
1-3:45 p.m.  

Taxol, tubulin, and tumors: A story of drug development
Susan Band Horwitz, PhD, Albert Einstein Medical College, Bronx, New York

Developing new approaches to difficult drug cancer targets
Nathanael S. Gray, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts

Additional speakers to be announced

Panel Discussion and Questions: Research and Development


Break
3:45-4:15 p.m.


Interactive Lab and Demo-cBioPortal: Cancer Genomics and Translational Research
4:15-6:15 p.m.

The cBioPortal for cancer genomics
Nikolaus Schultz, PhD, Memorial Sloan Kettering Cancer Center, New York, New York
Ethan Cerami, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts


Evening on Own
6:15 p.m.-


Top of page


Thursday, Nov. 8 

Continental Breakfast
7:45-8:45 a.m.


Offsite Patient Clinic Visits

8:45 a.m.-12 p.m.
Dana-Farber Cancer Institute
Massachusetts General Hospital
*Transportation will be provided.


Buffet Lunch
12-1 p.m.


Targeted Medicine
1-3:30 p.m.

Genomic analysis of cell-free plasma DNA
Geoffrey R. Oxnard, MD, Dana-Farber Cancer Institute, Boston, Massachusetts

Biomarkers and molecular diagnostics: The problem of patient selection
Maureen Cronin, PhD, Celgene Corporation, San Francisco, California

Additional speakers to be announced

Panel Discussion and Questions: Targeted Medicine


Break
3:30-4 p.m.


Panel Discussion on Entrepreneurship in Translational Research
4-5:30 p.m.

Deborah Dunsire, MD, XTuit Pharmaceuticals, Waltham, Massachusetts
Sangeeta N. Bhatia, MD, PhD, Massachusetts Institute of Technology, Cambridge, Massachusetts
Chi Van Dang, MD, PhD, Ludwig Institute for Cancer Research, New York, New York
Cigall Kadoch, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts
Alexis Borisy, Third Rock Ventures, LLC, Boston, Massachusetts


Dinner
5:30-6:30 p.m.


Special Seminar and Group Discussion: Unleashing the Power of Immune System – Focus on Translational Immunology
6:30-8 p.m.   

From basic science to cancer immunotherapy: T cell-mediated anti-tumor immunity
Kai W. Wucherpfennig, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts

Additional speaker to be announced


Top of page


Friday, Nov. 9 

Continental Breakfast
7-8 a.m.


Translating Differently
8-10:45 a.m.

Precision head and neck cancer medicine
Jennifer R. Grandis, MD, University of California, San Francisco, California

Additional speakers to be announced


Closing Remarks
10:45-11 a.m.

George D. Demetri, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Susan Band Horwitz, PhD, Albert Einstein College of Medicine, Bronx, New York
Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts


Post-Test / Evaluation
11 a.m.-12 p.m.


Attendee Departure
12:15 p.m.


Top of page